{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:31:05Z","timestamp":1787725865741,"version":"build-2784847793"},"reference-count":29,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Although nivolumab plus ipilimumab has become a standard treatment regimen for metastatic clear cell renal cell carcinoma (ccRCC), its efficacy in non\u2010clear cell carcinoma (nccRCC) has not been fully examined. In the current study, we evaluated the clinical outcomes of nivolumab plus ipilimumab in nccRCC compared with ccRCC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively analyzed 22 patients with metastatic and\/or locally advanced unresectable nccRCC who received nivolumab plus ipilimumab as a first\u2010line therapy and compared them with 107 patients with ccRCC. Objective response rate (ORR), progression\u2010free survival (PFS), overall survival (OS), and toxicity were compared between the nccRCC and ccRCC groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The histology of nccRCC included eight papillary, six unclassified, three chromophobe, two collecting duct carcinoma, and three other subtypes. Best objective response in nccRCC patients included three complete responses and five partial responses, resulting in an ORR of 36%, while that in ccRCC patients was 50% (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.22). With a median follow\u2010up of 11.9\u00a0months, OS was significantly shorter in patients with nccRCC than in those with ccRCC (median 20.8\u00a0months vs. not reached, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.04), while there was no significant difference in PFS (median 6.3 vs. 10.8\u00a0months, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.21). Treatment\u2010related adverse events occurred in 14 (64%) nccRCC patients and 81 (76%) ccRCC patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Combination treatment with nivolumab and ipilimumab demonstrated modest clinical efficacy in patients with nccRCC compared with patients with ccRCC, suggesting it could be a therapeutic option for metastatic nccRCC patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/iju.15128","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T09:16:44Z","timestamp":1671614204000},"page":"714-721","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non\u2010clear cell renal cell carcinoma: Real\u2010world data from a Japanese multicenter retrospective study"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9785-6432","authenticated-orcid":false,"given":"Keita","family":"Izumi","sequence":"first","affiliation":[{"name":"Department of Urology Saitama Cancer Center  Kita\u2010adachi\u2010gun Saitama Japan"},{"name":"Department of Urology Dokkyo Medical University Saitama Medical Center  Koshigaya Saitama Japan"},{"name":"Musashino Study Group  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0135-1203","authenticated-orcid":false,"given":"Masaharu","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Urology Saitama Cancer Center  Kita\u2010adachi\u2010gun Saitama Japan"},{"name":"Musashino Study Group  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9464-6424","authenticated-orcid":false,"given":"Satoshi","family":"Washino","sequence":"additional","affiliation":[{"name":"Musashino Study Group  Saitama Japan"},{"name":"Department of Urology Jichi Medical University Saitama Medical Center  Omiya\u2010ku Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Shirotake","sequence":"additional","affiliation":[{"name":"Musashino Study Group  Saitama Japan"},{"name":"Department of Uro\u2010Oncology Saitama Medical University International Medical Center  Hidaka Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kagawa","sequence":"additional","affiliation":[{"name":"Musashino Study Group  Saitama Japan"},{"name":"Department of Urology Saitama Medical Center, Saitama Medical University  Kawagoe Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Takeshita","sequence":"additional","affiliation":[{"name":"Musashino Study Group  Saitama Japan"},{"name":"Department of Urology Saitama Medical Center, Saitama Medical University  Kawagoe Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Miura","sequence":"additional","affiliation":[{"name":"Musashino Study Group  Saitama Japan"},{"name":"Department of Medical Oncology Toranomon Hospital  Minato\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Hyodo","sequence":"additional","affiliation":[{"name":"Department of Urology Dokkyo Medical University Saitama Medical Center  Koshigaya Saitama Japan"},{"name":"Musashino Study Group  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Oyama","sequence":"additional","affiliation":[{"name":"Department of Uro\u2010Oncology Saitama Medical University International Medical Center  Hidaka Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Urology Saitama Medical Center, Saitama Medical University  Kawagoe Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Miyagawa","sequence":"additional","affiliation":[{"name":"Department of Urology Jichi Medical University Saitama Medical Center  Omiya\u2010ku Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Urology Dokkyo Medical University Saitama Medical Center  Koshigaya Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Kageyama","sequence":"additional","affiliation":[{"name":"Department of Urology Saitama Cancer Center  Kita\u2010adachi\u2010gun Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology\u2010kidney cancer. V.1. 2023 [Internet]. National Comprehensive Cancer Network;2022Jun [cited 2022 Jun 30]. Available from:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12950"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.029"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00515-X"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.10.049"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00152-5"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.4809"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-001079"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34180"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.11.012"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaa229"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15557"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003844"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_13_21_1","unstructured":"US Department of Health and Human Services National Institutes of Health National Cancer Institute.Common Terminology Criteria for Adverse Events (CTCAE) version 5 [Internet].2017Nov [cited 2022 Jun 30]. Available from:https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0983"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu445"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505917"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01944"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.03.015"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.4378"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4597"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.15128","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/iju.15128","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.15128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T09:11:39Z","timestamp":1702717899000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.15128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/iju.15128"],"URL":"https:\/\/doi.org\/10.1111\/iju.15128","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,21]]},"assertion":[{"value":"2022-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}